scholarly journals Review: Considerations in Current Treatment of COVID-19 in Patients with Chronic Kidney Disease

2021 ◽  
Vol 6 (1) ◽  
Author(s):  
Dojcsak Ashley ◽  
Hasni Kamran ◽  
Sroya Hafiz
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Current Treatment

scholarly journals Cardiac Remodeling in Chronic Kidney Disease

Toxins ◽  
2020 ◽  
Vol 12 (3) ◽  
pp. 161 ◽  
Author(s):  
Nadine Kaesler ◽  
Anne Babler ◽  
Jürgen Floege ◽  
Rafael Kramann
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Cardiac Remodeling ◽  
Mineral Metabolism ◽  
Treatment Options ◽  
Renin Angiotensin System ◽  
Cell Types ◽  
Current Treatment ◽  
Left Ventricular ◽  
Heart Functions

Cardiac remodeling occurs frequently in chronic kidney disease patients and affects quality of life and survival. Current treatment options are highly inadequate. As kidney function declines, numerous metabolic pathways are disturbed. Kidney and heart functions are highly connected by organ crosstalk. Among others, altered volume and pressure status, ischemia, accelerated atherosclerosis and arteriosclerosis, disturbed mineral metabolism, renal anemia, activation of the renin-angiotensin system, uremic toxins, oxidative stress and upregulation of cytokines stress the sensitive interplay between different cardiac cell types. The fatal consequences are left-ventricular hypertrophy, fibrosis and capillary rarefaction, which lead to systolic and/or diastolic left-ventricular failure. Furthermore, fibrosis triggers electric instability and sudden cardiac death. This review focuses on established and potential pathophysiological cardiorenal crosstalk mechanisms that drive uremia-induced senescence and disease progression, including potential known targets and animal models that might help us to better understand the disease and to identify novel therapeutics.

scholarly journals SYMPATHETIC HYPERACTIVITY IN CHRONIC KIDNEY DISEASE PATIENTS: FROM PATHOGENESIS TO TREATMENT

2017 ◽  
pp. 141-160
Author(s):  
N. Stepanova
Keyword(s):  
Chronic Kidney Disease ◽  
Nervous System ◽  
Kidney Disease ◽  
Sympathetic Nervous System ◽  
Crucial Role ◽  
Clinical Relevance ◽  
Cardiovascular Complications ◽  
Current Treatment ◽  
Sympathetic Hyperactivity ◽  
Sympathetic Nervous

Sympathetic nervous system plays a crucial role in the development of cardiovascular complications in chronic kidney disease (CKD) patients. The aim of this review is to summarize up-to-date knowledge of the sympathetic hyperactivity in the pathogenesis of CKD, its clinical relevance, and as the options of current treatment.

scholarly journals Chronic Kidney Disease: Current Scenario of diagnosis and treatment in India

2021 ◽  
Author(s):  
Bhavya V
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Low Income ◽  
Conventional Treatment ◽  
Treatment Options ◽  
Current Treatment ◽  
Low Income Countries ◽  
Specific Marker ◽  
Treatment Scenario ◽  
Current Scenario

Chronic Kidney Disease (CKD) is one of the most burdensome disease with high mortality rate globally. Even though there are diagnostically accepted markers for the detection of CKD, the unreliability of the non-specific marker is a lacuna in the clinical world for an early prognosis and prevention of this chronic disease. Further, the economically challenging conventional treatment options available currently are a burden for many low-income countries to overcome this disease. This article discusses the current treatment scenario for CKD, and limitations of the diagnostic and treatment options available for CKD.

scholarly journals New Insights to the Crosstalk between Vascular and Bone Tissue in Chronic Kidney Disease–Mineral and Bone Disorder

Metabolites ◽  
2021 ◽  
Vol 11 (12) ◽  
pp. 849
Author(s):  
Maria L. Mace ◽  
Søren Egstrand ◽  
Marya Morevati ◽  
Klaus Olgaard ◽  
Ewa Lewin
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Bone Metabolism ◽  
Bone Tissue ◽  
Bone Development ◽  
Current Treatment ◽  
Mineral And Bone Disorder ◽  
Active Player ◽  
Organ Systems ◽  
Bone Disorder

Vasculature plays a key role in bone development and the maintenance of bone tissue throughout life. The two organ systems are not only linked in normal physiology, but also in pathophysiological conditions. The chronic kidney disease–mineral and bone disorder (CKD-MBD) is still the most serious complication to CKD, resulting in increased morbidity and mortality. Current treatment therapies aimed at the phosphate retention and parathyroid hormone disturbances fail to reduce the high cardiovascular mortality in CKD patients, underlining the importance of other factors in the complex syndrome. This review will focus on vascular disease and its interplay with bone disorders in CKD. It will present the very late data showing a direct effect of vascular calcification on bone metabolism, indicating a vascular-bone tissue crosstalk in CKD. The calcified vasculature not only suffers from the systemic effects of CKD but seems to be an active player in the CKD-MBD syndrome impairing bone metabolism and might be a novel target for treatment and prevention.

scholarly journals Metabolomics Evaluation of Patients With Stage 5 Chronic Kidney Disease Before Dialysis, Maintenance Hemodialysis, and Peritoneal Dialysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Sang Zhu ◽  
Feng Zhang ◽  
Ai-Wen Shen ◽  
Bo Sun ◽  
Tian-Yi Xia ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Peritoneal Dialysis ◽  
Kidney Disease ◽  
High Performance ◽  
Treatment Options ◽  
Plasma Concentrations ◽  
Current Treatment ◽  
Maintenance Hemodialysis ◽  
Liquid Chromatography Tandem Mass ◽  
The Impact

ObjectiveCurrent treatment options for patients with stage 5 chronic kidney disease before dialysis (predialysis CKD-5) are determined by individual circumstances, economic factors, and the doctor’s advice. This study aimed to explore the plasma metabolic traits of patients with predialysis CKD-5 compared with maintenance hemodialysis (HD) and peritoneal dialysis (PD) patients, to learn more about the impact of the dialysis process on the blood environment.MethodsOur study enrolled 31 predialysis CKD-5 patients, 31 HD patients, and 30 PD patients. Metabolite profiling was performed using a targeted metabolomics platform by applying an ultra-high-performance liquid chromatography-tandem mass spectrometry method, and the subsequent comparisons among all three groups were made to explore metabolic alterations.ResultsCysteine metabolism was significantly altered between predialysis CKD-5 patients and both groups of dialysis patients. A disturbance in purine metabolism was the most extensively changed pathway identified between the HD and PD groups. A total of 20 discriminating metabolites with large fluctuations in plasma concentrations were screened from the group comparisons, including 2-keto-D-gluconic acid, kynurenic acid, s-adenosylhomocysteine, L-glutamine, adenosine, and nicotinamide.ConclusionOur study provided a comprehensive metabolomics evaluation among predialysis CKD-5, HD, and PD patients, which described the disturbance of metabolic pathways, discriminating metabolites and their possible biological significances. The identification of specific metabolites related to dialysis therapy might provide insights for the management of advanced CKD stages and inform shared decision-making.

Renal anemia: from incurable to curable

2013 ◽  
Vol 305 (9) ◽  
pp. F1239-F1248 ◽  
Author(s):  
Yuki Sato ◽  
Motoko Yanagita
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Potential Risk ◽  
Clinical Effectiveness ◽  
Current Treatment ◽  
Renal Anemia ◽  
Future Directions ◽  
Therapeutic Trials ◽  
Relative Deficiency ◽  
Underlying Pathophysiology

Renal anemia has been recognized as a characteristic complication of chronic kidney disease. Although many factors are involved in renal anemia, the predominant cause of renal anemia is a relative deficiency in erythropoietin (EPO) production. To date, exogenous recombinant human (rh)EPO has been widely used as a powerful drug for the treatment of patients with renal anemia. Despite its clinical effectiveness, a potential risk for increased mortality has been suggested in patients who receive rhEPO, in addition to the economic burden of rhEPO administration. The induction of endogenous EPO is another therapeutic approach that might have advantages over rhEPO administration. However, the physiological and pathophysiological regulation of EPO are not fully understood, and this lack of understanding has hindered the development of an endogenous EPO inducer. In this review, we will discuss the current treatment for renal anemia and its drawbacks, provide an overview of EPO regulation in healthy and diseased conditions, and propose future directions for therapeutic trials that more directly target the underlying pathophysiology of renal anemia.

Sign in / Sign up

Export Citation Format

Share Document